bioMérieux receives Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

27 Mar 2024 18:01 CET

Subscribe
Issuer

BIOMERIEUX

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1240143_PR_bioMrieux_SPOTFIRE_RST_Panel_FDA_Clearance_20240327.pdf

Source

BIOMERIEUX

Provider

Les Echos

Company Name

BIOMERIEUX

ISIN

FR0013280286

Symbol

BIM

Market

Euronext

Attachments

  • Original Link
  • Permalink

Disclaimer

BioMérieux SA published this content on 27 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 March 2024 17:12:52 UTC.